Additionally, pairing glycolytic inhibitors with targeted therapies targeting key signaling pathways (e.g., PI3K/Akt/mTOR) could improve treatment outcomes by disrupting both tumor metabolism and essential survival signals. This evidence concerns the gene AKT1 and neoplasm.